Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Additions to SISCAPA Assay Technologies and More

Premium

SISCAPA Assay Technologies this week appointed Gustavo Salem to its board of directors and hired Ian Wright as a consultant and primary architect of diagnostic business strategy.

Salem was previously vice president and general manager of LC/MS at Agilent Technologies. Before that he was president and CEO of Assay Designs. He was also division manager of the Protein Separations Division at Bio-Rad.

Wright was previously head of the Strategic Innovation group and head of Global Assay Development at Siemens Healthcare Diagnostics.


Predictive Biosciences has named Pierre Cassigneul to be its new CEO, replacing Marc Schneebaum, who will return to his post as COO.

Cassigneul formerly was president, CEO, and vice chairman of the board at XDx, and he previously held management roles at Abbott Laboratories, Becton Dickinson, Bayer Diagnostics, and Ortho Diagnostic Systems. He also has served on the board of the Personalized Medicine Coalition.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.